Seres Therapeutics Inc (MCRB) - Total Assets
Based on the latest financial reports, Seres Therapeutics Inc (MCRB) holds total assets worth $143.47 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See net assets of Seres Therapeutics Inc for net asset value and shareholders' equity analysis.
Seres Therapeutics Inc - Total Assets Trend (2012–2024)
This chart illustrates how Seres Therapeutics Inc's total assets have evolved over time, based on quarterly financial data.
Seres Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Seres Therapeutics Inc's total assets of $143.47 Million consist of 27.7% current assets and 72.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 22.0% |
| Accounts Receivable | $4.75 Million | 3.4% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how Seres Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Seres Therapeutics Inc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Seres Therapeutics Inc's current assets represent 27.7% of total assets in 2024, a decrease from 95.5% in 2012.
- Cash Position: Cash and equivalents constituted 22.0% of total assets in 2024, down from 95.1% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 3.4% of total assets.
Seres Therapeutics Inc Competitors by Total Assets
Key competitors of Seres Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥26.08 Billion |
|
Staidson Beijing Biopharma
SHE:300204
|
China | CN¥1.26 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.64 Billion |
|
Ardelyx Inc
NASDAQ:ARDX
|
USA | $486.17 Million |
|
Xiangxue Pharmaceutical
SHE:300147
|
China | CN¥7.36 Billion |
Seres Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.30 | 1.12 | 5.79 |
| Quick Ratio | 2.30 | 1.12 | 5.79 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $29.10 Million | $8.10 Million | $222.36 Million |
Seres Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Seres Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.75 |
| Latest Market Cap to Assets Ratio | 0.49 |
| Asset Growth Rate (YoY) | -61.0% |
| Total Assets | $139.81 Million |
| Market Capitalization | $68.84 Million USD |
Valuation Analysis
Below Book Valuation: The market values Seres Therapeutics Inc's assets below their book value (0.49x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Seres Therapeutics Inc's assets decreased by 61.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Seres Therapeutics Inc (2012–2024)
The table below shows the annual total assets of Seres Therapeutics Inc from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $139.81 Million | -61.01% |
| 2023-12-31 | $358.60 Million | +2.81% |
| 2022-12-31 | $348.78 Million | -1.71% |
| 2021-12-31 | $354.86 Million | +3.48% |
| 2020-12-31 | $342.94 Million | +158.94% |
| 2019-12-31 | $132.44 Million | +9.93% |
| 2018-12-31 | $120.47 Million | -36.43% |
| 2017-12-31 | $189.52 Million | -30.49% |
| 2016-12-31 | $272.65 Million | +25.70% |
| 2015-12-31 | $216.90 Million | +84.84% |
| 2014-12-31 | $117.34 Million | +5422.12% |
| 2013-12-31 | $2.12 Million | -67.50% |
| 2012-12-31 | $6.54 Million | -- |
About Seres Therapeutics Inc
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize gastrointestinal pathogens, enhance epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outc… Read more